Skip to main content
Erschienen in: International Cancer Conference Journal 4/2016

28.04.2016 | Case report

Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs

verfasst von: Shunsuke Sugiyama, Mariko Ishizuka, Masanobu Takahashi, Keigo Komine, Hiroo Imai, Ken Saijo, Masahiro Takahashi, Hidekazu Shirota, Shin Takahashi, Hideki Shimodaira, Chikashi Ishioka

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

A 60-year-old woman was admitted to a medical clinic because of epigastric pain. Esophagogastroduodenoscopy revealed a submucosal tumor in the upper gastric corpus and, the tumor was subsequently resected using partial gastrectomy. The pathological findings revealed that the tumor was a gastrointestinal stromal tumor. After 4 months of observation without any adjuvant treatment, the patient was found to have liver metastasis and she was admitted to our hospital for treatment. We successfully treated the patient through sequential drug therapies, including imatinib, nilotinib, sunitinib, and regorafenib, and maintaining disease control for more than 5 years.
Literatur
1.
Zurück zum Zitat Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comp Cancer Netw 8(Suppl 2):S1–S41 (quiz S42–44) Demetri GD, von Mehren M, Antonescu CR et al (2010) NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Comp Cancer Netw 8(Suppl 2):S1–S41 (quiz S42–44)
2.
Zurück zum Zitat Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480CrossRefPubMed Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480CrossRefPubMed
3.
Zurück zum Zitat Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625CrossRefPubMed Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625CrossRefPubMed
4.
Zurück zum Zitat Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338CrossRefPubMed Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338CrossRefPubMed
5.
Zurück zum Zitat Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302CrossRefPubMed Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302CrossRefPubMed
6.
Zurück zum Zitat Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419CrossRefPubMed Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39:1411–1419CrossRefPubMed
7.
Zurück zum Zitat Rutkowski P, Bylina E, Wozniak A et al (2011) Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 37:890–896CrossRefPubMed Rutkowski P, Bylina E, Wozniak A et al (2011) Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour: the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 37:890–896CrossRefPubMed
8.
Zurück zum Zitat Blay JY, Shen L, Kang YK et al (2015) Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 16:550–560CrossRefPubMedPubMedCentral Blay JY, Shen L, Kang YK et al (2015) Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 16:550–560CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
10.
Zurück zum Zitat Sawaki A, Nishida T, Doi T et al (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117:4633–4641CrossRefPubMed Sawaki A, Nishida T, Doi T et al (2011) Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 117:4633–4641CrossRefPubMed
11.
Zurück zum Zitat Kang YK, Ryu MH, Yoo C et al (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14:1175–1182CrossRefPubMedPubMedCentral Kang YK, Ryu MH, Yoo C et al (2013) Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 14:1175–1182CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774CrossRefPubMed Heinrich MC, Corless CL, Blanke CD et al (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24:4764–4774CrossRefPubMed
13.
Zurück zum Zitat Komatsu Y, Doi T, Sawaki A et al (2015) Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol 20:905–912CrossRefPubMedPubMedCentral Komatsu Y, Doi T, Sawaki A et al (2015) Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol 20:905–912CrossRefPubMedPubMedCentral
Metadaten
Titel
Successful sequential treatment of a patient with advanced gastrointestinal stromal tumor using four different molecularly targeted drugs
verfasst von
Shunsuke Sugiyama
Mariko Ishizuka
Masanobu Takahashi
Keigo Komine
Hiroo Imai
Ken Saijo
Masahiro Takahashi
Hidekazu Shirota
Shin Takahashi
Hideki Shimodaira
Chikashi Ishioka
Publikationsdatum
28.04.2016
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2016
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-016-0250-1

Weitere Artikel der Ausgabe 4/2016

International Cancer Conference Journal 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.